-
Overview
Date & Location
11/8/2020 - 11/8/2021, 12:00AM CST Online
Overview
This podcast discusses new and emerging therapies for COVID-19 to include the efficacy of the antiviral remdesivir and it use in COVID-19 patients as well as other candidate treatments currently being studied for COVID-19 hospitalized patients. The potential role of monoclonal antibodies in COVID-19 treatment is also discussed.
Target Audience
This educational activity is designed to meet the educational goals of physicians and other healthcare professionals specializing in infectious diseases, family and community medicine, internal medicine, emergency medicine, and all those involved with the management of patients with coronavirus.
Learning Objectives for the Episode 1
- Discuss the efficacy of the antiviral remdesivir and when it should be used in COVID-19 patients
- List other candidate treatments being studied for the treatment of COVID-19 in hospitalized patients
- Describe the potential role of monoclonal antibodies in treating COVID-19
Program Registration Information
Registration Fees - $0.00
Continuing Medical Education Education Credit - Accreditation and Designation Statement
The Joe R. and Teresa Lozano Long School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Long School of Medicine designates this enduring material for a maximum of .25 AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Certificate of Attendance
Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance.
Credit may be obtained upon successful completion of the activity’s evaluation.
Release date: 11/8/2020 Credits expire: 11/8/2021
-
Faculty
Jan E. Patterson, MD, MS, MACP
FIDSA, FSHEA, CHCP
Professor of Medicine/Infectious Diseases and Pathology
Associate Dean for Quality & Lifelong Learning
Joe R. and Teresa Lozano Long School of Medicine
ºÚÁÏÍøDr. Patterson is a Professor of Medicine/Infectious Diseases and Associate Dean for Quality & Lifelong Learning at The Joe R. and Teresa Lozano Long School of Medicine, ºÚÁÏÍø. She is clinician and a healthcare epidemiologist and has served on the Infectious Diseases Society of America Board of Directors and is Past President of the Society for Healthcare Epidemiology of America. She is a longtime infectious diseases consultant to Southwest Texas Regional Advisory Council (STRAC) and has also served on CDC’s Healthcare Infection Control Practices Advisory Committee and has been a consultant to the City of San Antonio Metro Health Department. She has been a site principal investigator for new antimicrobial agents and is currently a co-investigator for the NIH ACTT studies as outlined above and is a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health SA and University Hospital.
Thomas F. Patterson, MD
Professor of Medicine/Infectious Diseases and Pathology
Division Chief, Infectious Diseases
Vice Chair for Faculty Development
Joe R. and Teresa Lozano Long School of Medicine
ºÚÁÏÍøDr. Patterson is a Professor of Medicine and Chief, Division of Infectious Diseases and serves as the Vice-Chair for Faculty Development in the Department of Medicine at The Joe R. and Teresa Lozano Long School of Medicine, ºÚÁÏÍø. He is a clinician and longtime clinical investigator, particularly in the development of new antifungal drugs and in clinical trials of new antifungal compounds. He has had long-term funding from the NIH and industry for grants and contracts on drug and diagnostic development. During this COVID-19 pandemic, Dr. Patterson leads the UT Health Division of Infectious Diseases efforts in clinical management of COVID-19 care and is the site principal investigator for the Adaptive COVID-19 Treatment Trial (ACTT) conducted at University Hospital and supported by the National Institutes of Health to develop safe and effective therapies against COVID-19. He is a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at UT Health SA and University Hospital.
Relevant Financial Disclosures
Dr. Jan Patterson has disclosed that she is a NIH ACTT co-investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial. She is the spouse of Dr. Thomas Patterson.
Dr. Tom Patterson has disclosed that he is a NIH ACTT investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial. He is the spouse of Dr. Jan Patterson.
